EMA

The EMA is the most over-read regulator in this sector, and in our opinion the single most common mistake a reader makes is treating an EMA approval as market access. It is not. An approval is permission to sell. Whether a health system buys, at what price, and for which patients is decided country by country, after the EMA has finished. So an EMA filing is a real milestone for a company and a weak one for a European patient, and a press release that leads on the agency without naming a reimbursement route is telling you about the easier half of the problem. The second reading error is direction. A drug can run trials in nine EU countries and still have asked no European regulator for permission to sell, because those are two different applications to two different processes.

Does the EMA set drug prices? No. We put the division of labour plainly in Issue 8: "A centralised approval is valid across every member state on the day it lands. The EMA states plainly that it has no role in decisions on pricing and reimbursement, which happen at national and regional level. The Joint Clinical Assessment framework, applicable since January 2025, harmonises the clinical review across member states and leaves the money decision exactly where it was."

We had made the same point a week earlier in Issue 7, reading the Lilly purchase of AtaiBeckley: "The centralised procedure would give either drug one marketing authorisation valid across all EU and EEA states, but the EMA has no role in price. That stays national." Our conclusion there was that the single-approval efficiency Europe does offer "stops exactly at the point where money changes hands."

A trial authorisation is not a marketing application. This distinction runs through the whole beat and we set it out in Issue 11: "A clinical trial authorisation lets you study a drug in a member state. A marketing authorisation application asks permission to sell it." Compass Pathways has run trials across nine European countries and, as of our last check of the EMA's list of applications under evaluation, had asked no European regulator for permission to sell the result.

The agency does have a route short of a filing. In our H1 2026 review we recorded bretisilocin becoming the first psychedelic compound accepted into the EMA's PRIME priority medicines scheme, and were careful about what that is: "PRIME is not approval and not even a filing; it is an enhanced regulatory dialogue."